drugset / Trial / NCT00667576

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

NCT00667576

Phase 2 Completed 153 enrolled Abbott Abbott Japan Co.,Ltd · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to investigate the initial dose and dose adjustment range for paricalcitol injection in patients with chronic kidney disease on hemodialysis who have secondary hyperparathyroidism.

Timeline

Start
2008-04
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Paricalcitol Other / unclassified 2 ug Intravenous
Subject Paricalcitol Other / unclassified 4 ug Intravenous
Subject maxacalcitol Small molecule 5 ug Intravenous
Subject maxacalcitol Small molecule 10 ug Intravenous